Effector Mechanism and Clinical Response of BAK (BRM-Acrivated Killer) Immuno-Cell Therapy for Maintaining Satisfactory QOL of Advanced Cancer Patients Utilizing CD56-Positive NIE (Neuro-Immune-Endocrine) Cells
スポンサーリンク
概要
- 論文の詳細を見る
- Center for Academic Pub. Japanの論文
- 2001-05-20
著者
-
EBINA Takusaburo
Division of Immunology, Research Institute Miyagi Cancer Center
-
Isono N
Division Of Immunology Miyagi Cancer Center Research Institute
-
OGAMA Naoko
Division of Immunology, Miyagi Cancer Center Research Institute
-
SHIMANUKI Hiroko
Division of Immunology, Miyagi Cancer Center Research Institute
-
KUBOTA Tomoka
Division of Immunology, Miyagi Cancer Center Research Institute
-
ISONO Noriko
Division of Immunology, Miyagi Cancer Center Research Institute
-
Ogama Naoko
Division Of Immunology Miyagi Cancer Center Research Institute
-
Kubota Tomoka
Division Of Immunology Miyagi Cancer Center Research Institute
-
Shimanuki Hiroko
Division Of Immunology Miyagi Cancer Center Research Institute
-
Ebina Takusaburo
Division of Immunology, Miyagi Cancer Center Research Institute
関連論文
- A High-Mr Glycoprotein Fraction from Cow's Milk Potent in Inhibiting Replication of Human Rotavirus in Vitro
- Morphological Observations on Antitumor Activities of 70kDa Fragment in α-Subunit from Pronase-Treated Ovomucin in a Double Grafted Tumor System
- Oral Passive Immunization Effect of Anti-Human Rotavirus IgY and Its Behavior against Proteolytic Enzymes
- Effector Mechanism and Clinical Response of BAK (BRM-Acrivated Killer) Immuno-Cell Therapy for Maintaining Satisfactory QOL of Advanced Cancer Patients Utilizing CD56-Positive NIE (Neuro-Immune-Endocrine) Cells
- Bulk Cultures of Canine Peripheral Blood Lymphocytes with Solid Phase Anti-CD3 Antibody and Recombinant Interleukin-2 for Use in Immunotherapy.